Advancing Aptamer-Based Therapeutics: Unlocking CNS Delivery & Expanding the Potential of Oligo Modalities

• Explore how aptamer-based therapeutics can move beyond traditional delivery roles to directly modulate disease biology, unlocking new opportunities for targeting previously undruggable pathways in Parkinson’s disease
• Discover how early-stage discovery and in vitro validation of aptamers are shaping the next generation of CNS-targeting therapies and demonstrating functional activity
• Enable innovative therapeutic development by evaluating intrinsic oligonucleotide chemistry versus conjugation strategies, highlighting how modality design choices can influence CNS penetration, target engagement, and overall clinical potential

Speakers:

Ganesh Iyer

Chief Executive Officer & Founder

Opprtna